Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

Market Cap	4.53B -50.5%
Revenue (ttm)	852.85M +266.9%
Net Income	592.98M
EPS	0.77
Shares Out	783.09M
PE Ratio	7.55
Forward PE	16.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,948,100
Open	6.02
Previous Close	6.06
Day's Range	5.70 - 6.02
52-Week Range	3.98 - 11.58
Beta	0.33
Analysts	Buy
Price Target	9.82 (+69.9%)
Earnings Date	Aug 24, 2026

About HKG:1167

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic mal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 207
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1167

Financial Performance

In 2025, HKG:1167's revenue was 53.53 million, a decrease of -65.62% compared to the previous year's 155.71 million. Losses were -145.98 million, -6.25% less than in 2024.

Financial numbers in CNY

Analyst Summary

According to 2 analysts, the average rating for 1167 stock is "Buy." The 12-month stock price target is $9.82, which is an increase of 69.90% from the latest price.

Price Target

$9.82

(69.90% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error